A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

NCT ID: NCT06556368

Last Updated: 2025-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

675 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-23

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wet Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be randomized 1:1:1 into one of three treatment groups: tarcocimab-ted, tabirafusp-ted or aflibercept.
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tarcocimab tedromer 5 mg (KSI-301)

Intravitreal injection of tarcocimab tedromer once every 4 weeks for 4 monthly doses followed by individualized dosing every 4 to 24 weeks.

Group Type EXPERIMENTAL

Tarcocimab tedromer

Intervention Type DRUG

Intravitreal injection

Tabirafusp tedromer 5 mg (KSI-501)

Intravitreal injection of tabirafusp tedromer once every 4 weeks for 4 monthly doses followed by every-8-week dosing with additional individualized dosing (up to monthly dosing)

Group Type EXPERIMENTAL

Tabirafusp tedromer

Intervention Type DRUG

Intravitreal injection

Aflibercept 2 mg

Intravitreal injection of aflibercept once every 4 weeks for 3 monthly doses followed by every-8-week dosing

Group Type ACTIVE_COMPARATOR

Aflibercept

Intervention Type DRUG

Intravitreal injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tarcocimab tedromer

Intravitreal injection

Intervention Type DRUG

Tabirafusp tedromer

Intravitreal injection

Intervention Type DRUG

Aflibercept

Intravitreal injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

KSI-301 KSI-501 Eylea

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Active, treatment-naïve choroidal neovascularization (CNV) secondary to AMD, including subfoveal, juxtafoveal, and extrafoveal lesions, or retinal angiomatous proliferations (RAP) lesions with a CNV component that affects the central subfield, as evidenced by FA or OCT in the Study Eye at Screening
* BCVA ETDRS score between 78 and 25 letters (Snellen equivalent \~20/32 and 20/320) inclusive, in the Study Eye at screening and reconfirmed at Day 1.
* Capable of giving signed informed consent.

Exclusion Criteria

* BCVA of hand motion or worse in the non-Study Eye or non-physical presence of a non-Study Eye (i.e., monocular)
* Fibrosis or atrophy of \>50% of the lesion size and/or involving the foveal center of the Study Eye at Screening
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kodiak Sciences Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pablo Velazquez-Martin, MD

Role: STUDY_DIRECTOR

Kodiak Sciences Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Associated Retina Consultants

Gilbert, Arizona, United States

Site Status

Associated Retina Consultants

Phoenix, Arizona, United States

Site Status

Retina Macula Institute of Arizona

Scottsdale, Arizona, United States

Site Status

Retina Associates SW

Tucson, Arizona, United States

Site Status

Retina Consultants of Orange County

Fullerton, California, United States

Site Status

Global Research Management, Inc. - Lugene Eye Institute

Glendale, California, United States

Site Status

Retinal Consultants Medical Group, Inc.

Modesto, California, United States

Site Status

California Eye Specialists Medical Group, Inc.

Pasadena, California, United States

Site Status

California Eye Specialists Medical Group, Inc.

Redlands, California, United States

Site Status

Retinal Consultants Medical Group Inc

Sacramento, California, United States

Site Status

Retina Consultants of Southern Colorado

Colorado Springs, Colorado, United States

Site Status

Retina Group of New England, PC

Waterford, Connecticut, United States

Site Status

Blue Ocean Clinical Research

Clearwater, Florida, United States

Site Status

Retina Group of Florida

Fort Lauderdale, Florida, United States

Site Status

National Ophthalmic Research Institute

Fort Myers, Florida, United States

Site Status

Retina Group of Florida

Sarasota, Florida, United States

Site Status

Center for Retina and Macular Disease

Winter Haven, Florida, United States

Site Status

Southeast Retina Center

Augusta, Georgia, United States

Site Status

Retina Associates, Ltd

Elmhurst, Illinois, United States

Site Status

Illinois Retina Associates

Oak Park, Illinois, United States

Site Status

Associated Vitreoretinal and Uveitis Consultants LLC

Carmel, Indiana, United States

Site Status

Midwest Eye Institute

Carmel, Indiana, United States

Site Status

The Retina Care Center

Baltimore, Maryland, United States

Site Status

Cumberland Valley Retina Consultants

Hagerstown, Maryland, United States

Site Status

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States

Site Status

Retina Consultants of Minnesota

Edina, Minnesota, United States

Site Status

Retina Consultants of Minnesota

Saint Louis Park, Minnesota, United States

Site Status

Mississippi Retina Associates

Madison, Mississippi, United States

Site Status

The Retina Institute

St Louis, Missouri, United States

Site Status

Retina Consultants of Nevada

Henderson, Nevada, United States

Site Status

Long Island Vitreoretinal Consultants

Hauppauge, New York, United States

Site Status

Retina Vitreous Surgeons of CNY PC

Liverpool, New York, United States

Site Status

Retina Associates of Western NY

Rochester, New York, United States

Site Status

Asheville Eye Associates

Asheville, North Carolina, United States

Site Status

North Carolina Retina Associates

Cary, North Carolina, United States

Site Status

Piedmont Retina Specialist

Greensboro, North Carolina, United States

Site Status

Graystone Eye

Hickory, North Carolina, United States

Site Status

North Carolina Retina Associates

Wake Forest, North Carolina, United States

Site Status

Western Carolina Clinical Research, LLC

Winston-Salem, North Carolina, United States

Site Status

Retina Northwest

Portland, Oregon, United States

Site Status

Cascade Medical Research Institute

Springfield, Oregon, United States

Site Status

Erie Retina Research

Erie, Pennsylvania, United States

Site Status

Vision Research Solutions PLLC

Philadelphia, Pennsylvania, United States

Site Status

Palmetto Retina Center

Aiken, South Carolina, United States

Site Status

Charleston Neuroscience Institute, LLC

Beaufort, South Carolina, United States

Site Status

Charleston Neuroscience Institute, LLC

Charleston, South Carolina, United States

Site Status

Charleston Neuroscience Institute, LLC

Ladson, South Carolina, United States

Site Status

Charleston Neuroscience Institute

Mt. Pleasant, South Carolina, United States

Site Status

Palmetto Retina Center

West Columbia, South Carolina, United States

Site Status

Ophthalmology Ltd

Sioux Falls, South Dakota, United States

Site Status

Charles Retina Institute

Germantown, Tennessee, United States

Site Status

Retina Research Institute of Texas

Abilene, Texas, United States

Site Status

Panhandle Eye Group, LLP. - Southwest Retina Specialists

Amarillo, Texas, United States

Site Status

Texas Retina Associates

Arlington, Texas, United States

Site Status

Austin Research Center for Retina

Austin, Texas, United States

Site Status

Austin Retina Associates, PLLC

Austin, Texas, United States

Site Status

Retina Consultants of Texas

Bellaire, Texas, United States

Site Status

Star Vision Research

Burleson, Texas, United States

Site Status

Texas Retina Associates

Fort Worth, Texas, United States

Site Status

Texas Retina Center

Houston, Texas, United States

Site Status

Retina Consultants of Texas

Katy, Texas, United States

Site Status

Texas Retina Associates

Plano, Texas, United States

Site Status

Austin Retina Associates, PLLC

Round Rock, Texas, United States

Site Status

Retinal Consultants of Houston dba Retina Consultants of Texas

San Antonio, Texas, United States

Site Status

Retina Consultants of Texas

Schertz, Texas, United States

Site Status

Retina Consultants of Texas

The Woodlands, Texas, United States

Site Status

Strategic Clinical Research Group, LLC

Willow Park, Texas, United States

Site Status

Piedmont Eye Center

Lynchburg, Virginia, United States

Site Status

Pacific Northwest Retina

Bellevue, Washington, United States

Site Status

Spokane Eye Clinical Research

Spokane, Washington, United States

Site Status

Eye Clinic of Wisconsin

Wausau, Wisconsin, United States

Site Status

Emanuelli Research & Development Center, LLC

Arecibo, Puerto Rico, Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KS301P109

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AAVCAGsCD59 for the Treatment of Wet AMD
NCT03585556 COMPLETED PHASE1